1. Introduction {#s0005}
===============

Type 2 diabetes mellitus (T2DM) is characterized by elevated levels of blood glucose caused by the impairment in both insulin secretion and action. It usually begins as insulin resistance disorder in which the cells do not respond to insulin properly. As the need for insulin rises, pancreas gradually loses its ability to produce insulin. Insulin plays a key role in the glucose metabolism and the genes involved in the insulin pathway are of prime importance in dissecting the role of genetic factors in the etiology of T2DM. With the development of microarray platforms, genome-wide association studies (GWAS) have shed light on many novel genes showing strong association withT2DM. *Insulin growth factor 2 m-RNA binding protein 2* (*IGF2BP2*) and *Solute Carrier family 30 member 8* (*SLC30A8*) are two such genes which were identified only through GWAS and subsequently replicated in many populations across the globe ([@bb0135; @bb0145; @bb0170; @bb0175; @bb0180; @bb0190; @bb0195; @bb0200; @bb0220]).

The *IGF2BP2* gene is involved in insulin secretion, essential for glucose metabolism. This gene has shown conflicting results regarding the nature of its association with T2DM, particularly the two SNPs of this gene -- rs4402960 and rs1470579 -- that we have analyzed were the most commonly studied polymorphisms in different populations and yielded both strong ([@bb0015; @bb0025; @bb0075; @bb0080; @bb0085; @bb0090; @bb0105; @bb0130; @bb0185; @bb0205]) as well as weak or no association ([@bb0060; @bb0095; @bb0140]). The lack of consistency in these studies may be primarily attributed to the inadequate statistical power because of small sample size as well as ethnic variability. In view of the conflicting findings several meta-analyses were carried out and the results suggest that the variants of *IGF2BP2* confer increased risk for T2DM in the European and Asian populations ([@bb0110; @bb0215]). On the other hand, the *SLC30A8* gene is a member of zinc transporter family involved in the insulin secretion. This zinc transporter is involved in the process of Insulin synthesis, storage and secretion. This gene was identified in the first GWAS study of T2DM in French population ([@bb0175]) and subsequent replication studies and meta-analysis also confirmed its association with T2DM ([@bb0020; @bb0115]). The rs13266634 of *SLC30A8* gene is the most studied SNP showing strong association with T2DM ([@bb0015; @bb0075; @bb0085; @bb0105; @bb0100; @bb0150; @bb0210]), albeit a few studies were non-conformatory ([@bb0065; @bb0095; @bb0140]).

The rapid process of urbanization and adaption of western lifestyles by the Indians coupled with 'Asian Indian Phenotype' ([@bb0125]) makes the people of this country more vulnerable to develop T2DM and share greater burden of this global epidemic. Therefore, it is imperative to validate T2DM susceptible genes that were found associated in non-Indian populations among diverse ethnic and geographic populations of India. Although a couple of studies tested for association of *IGF2BP2* and *SLC30A8* gene variants with T2DM, an inconsistent pattern of association was observed in the North and South Indian populations with respect to these genes; while *IGF2BP2* showed strong association with T2DM in North Indians ([@bb0030; @bb0165]) it was not shown in the South Indians from Chennai ([@bb0035]). Further, within North India, the *SLC30A8* gene displayed both significant ([@bb0030]) and non-significant associations ([@bb0165]) with T2DM in two independent samples. In this context, it may be pertinent to note that in a recent study [@bb0155], based on comprehensive genetic data, suggest distinct origin and genetic architecture of north and south Indian populations. Therefore, it is necessary to test the pattern of association of these polymorphisms with T2DM in diverse ethnic and geographic populations within India in order to establish if the nature of association of these genes with T2DM is universal to the Indian populations, in general. The city of Hyderabad which is considered as diabetic capital of India and the population of Andhra Pradesh with putatively high and ever increasing prevalence of T2DM have not been hitherto studied for the nature of their genetic susceptibility. To the best of our knowledge, this is the first study dealing with the nature of genetic association of T2DM in the population of Andhra Pradesh, India. We report here the results of our study on the association of three SNPs of *IGF2BP2* (rs4402960, rs1470579-Intron2) and *SLC30A8* (rs13266634-cds) genes with T2DM in this specific population.

2. Materials & methods {#s0010}
======================

2.1. Study design {#s0015}
-----------------

This is a case--control study for which 758 T2DM cases (443 males and 315 females) and 621 controls (395 males and 226 females) were included. The T2DM patients were recruited from J.P. Endocrine Center, Hyderabad, based on their medical record and adhering to [@bb0010] criteria that specifies fasting plasma glucose(FPG) ≥ 126 mg/dl or 2 -h plasma glucose (PPG) ≥ 200 mg/dl or random plasma glucose (random blood sugar) (RBG) ≥ 200 mg/dl to be characterized as diabetic. We have conducted free diabetic camps for the employees of different organizations in Hyderabad and individuals with ≥ 40 years of age were tested for random blood sugar (where fasting and 2 -h plasma glucose were not feasible) and those having blood sugar \< 140 mg/dl and no identifiable positive family history were recruited as controls. The background information such as sex, present age, age at onset of T2DM, family history and the lifestyle parameters such as food habits, smoking, alcohol consumption and physical activity were gathered in the form of a questionnaire. Anthropometric measurements like height, weight, waist and hip circumferences were also collected and body mass index (BMI) and waist to hip ratio (WHR) were calculated. All the above mentioned information and measurements were collected on both cases and controls. About 5 ml of blood was collected from each of the T2DM cases and controls with written informed consent.

2.2. Ethics statement {#s0020}
---------------------

The study was approved by the Indian Statistical Institute Review Committee for Protection of Research Risks to Humans.

2.3. DNA extraction and genotyping {#s0025}
----------------------------------

We isolated DNA using the phenol--chloroform method ([@bb0160]). Quantification of the extracted DNA was performed using NanoDrop. The SNPs of *IGF2BP2* (rs4402960, rs1470579) and *SLC30A8* (rs13266634) genes, were genotyped, as part of a panel of 15 SNPs, on Sequenom Massarray platform ([@bb0070]) at the Centre for Genomic Application (TCGA), Delhi. The raw data files generated by Mass Array Sequenom were analyzed for the intensity peaks of calibrant to ascertain the quality of the data. An overall call rate of \> 95% was maintained. For every 96 samples (a quadrant of Sequenom chip), 4 samples were duplicated and the call rates were checked for concordance. The calls in the negative control (no DNA) were also monitored in all the runs.

2.4. Statistical analysis {#s0030}
-------------------------

Most of the statistical analyses were performed with the help of SPSS statistical software (version 18.0, IBM SPSS). Post-hoc power of the study was estimated using G\*Power software (version 3.1). The Hardy--Weinberg equilibrium was estimated by the *χ*^2^ test using Pypop software. Haploview software was used to obtain estimates of Linkage Disequilibrium.

3. Results {#s0035}
==========

3.1. Clinical profile of the subjects {#s0040}
-------------------------------------

[Table 1](#t0005){ref-type="table"} presents the clinical profile of the subjects represented by mean, median and range for different variables, viz., age of the subjects, age at onset of the disease, BMI, WHR, FPG, PPG, SBP and DBP. Overall, the sample, albeit not purposive, represents a relatively greater proportion of male subjects in the ratio of \~ 3:2. Broadly speaking, similar age range, mean and median values were presented by the cases and controls. However, the mean and median values of BMI, WHR and RBG of the cases were not only much higher than the controls but also highly significantly different (p \< 0.01) from them.

3.2. Allele and genotype frequencies {#s0045}
------------------------------------

The allele and genotype frequencies of the three SNPs are presented in [Tables 2 & 3](#t0010 t0015){ref-type="table"}. The observed genotype counts were found to be similar in frequency as compared to those expected under Hardy--Weinberg Equilibrium and the *χ*^2^ test suggests that all the three SNP loci conform to the Hardy--Weinberg equilibrium in both case and control samples. Further, the two SNPs of *IGF2BP2* located in the intron 2 were found to be in strong LD with D′ = 0.99 and r^2^ = 0.98 ([Fig. 1](#f0005){ref-type="fig"}). The allele and genotype frequencies were similar between cases and controls in case of both the genes. The logistic regression analysis did not reveal significant allelic or genotypic association of any of the three SNPs with T2DM. The logistic regression with BMI and WHR as covariates suggests significant effect of covariates, not of genotypes ([Table 3](#t0015){ref-type="table"}).

3.3. Power of the study {#s0050}
-----------------------

Given non-significant nature of association of these two genes in our sample, it is necessary to estimate if our study has adequate power to detect the true association if present in the population. We estimated the power of our study by using the effect size (log of odds ratio) reported in a previous Indian study ([@bb0030]) that showed significant association of two of the 3 SNPs of the *IGF2BP2* and *SLC30A8* genes. Given the effect sizes of 0.079 (log of 1.20) and 0.127 (log of 1.34) for the two SNPs in the reference population, and with our study sample of 1379, we obtained the power of 83% and 99% at p = 0.05, for the two SNPs of *IGF2BP2* and *SLC30A8* genes, respectively. This shows that our sample size of 1379 was adequate and the study was sufficiently-powered to detect the true association of these genes with T2DM, if existent in this population. We also estimated the minimum effect size (log of OR) required for our study to detect true association (p = 0.05) with 90% power to be 0.087, for both the genes. However, the observed effect size was far smaller (0.04) than the estimated 0.087 in case of both the *IGF2BP2* SNPs where it was close to zero (− 0.02) in case of the lone SNP studied for *SLC30A8*, suggesting lack of association of these SNPs with T2DM in this population.

3.4. Comparative analysis with previous Indian studies {#s0055}
------------------------------------------------------

Given the inconsistent nature of findings on the association of these genes with T2DM in the Indian populations, we tried to collate information from the previous three studies on Indian populations ([Table 4](#t0020){ref-type="table"}) and realized that only two of the three studies, besides ours, presented allele frequency data for two of the three SNPs (rs4402960, rs13266634) that we studied. However, the test for homogeneity of allele frequencies across the three Indian populations suggests significant heterogeneity for each of the two SNPs ([Table 4](#t0020){ref-type="table"}), possibly underlining the ethnic and genetic heterogeneity implicit among Indian populations. Given this, meta-analysis may not be appropriate albeit one of the two SNPs (rs4402960) shows significant association with T2DM in a north Indian population ([@bb0165]).

4. Discussion {#s0060}
=============

Despite large sample size and adequate statistical power of our study, we could not replicate the association of *IGF2BP2* and *SLC30A8* SNPs with T2DM in our sample from Hyderabad, India. However, our results are consistent with the other South Indian study from Chennai ([@bb0035]) which also did not reveal significant association of these genes with T2DM, despite analyzing much larger set of samples than that of ours. There was also no consistent evidence of association of these genes among populations of London, Pakistan and Singapore with South Indian ancestry ([@bb0120]). On the other hand, a north Indian study ([@bb0030]), which included by far the largest sample from India showed significant association of these two genes with T2DM, albeit within northern India, two independent samples displayed contrasting results ([@bb0030; @bb0165]). It may be pertinent to note that broadly speaking the southern Indian populations represent similar linguistic and ethnic backgrounds and possibly reflect similar genetic architecture as compared to the Northern Indian populations ([@bb0155]). This inconsistent pattern of genetic association with T2DM among different regional and/or ethnic populations of India and/or between Indian and western populations could be due to ethnic variation with implicit heterogeneity of the frequency of the susceptible genetic variants across regional/ethnic groups both within India ([Table 4](#t0020){ref-type="table"}) and across the globe. The unique Indian population structure with enormous genetic heterogeneity implicit among the ethnic groups within India, particularly between the southern Indian and northern Indian populations ([@bb0155]) underlines the importance of studying different ethnic and geographic populations of India in order to draw a representative susceptible/protective genetic profile for India that may be associated with T2DM. Although couple of studies performed meta-analysis which revealed increased risk conferred by these genes towards developing T2DM among South and East Asian populations along with Europeans ([@bb0110; @bb0215; @bb0020; @bb0115]), given the significant allelic heterogeneity among the three Indian populations for which data were available ([Table 4](#t0020){ref-type="table"}) and considering the fact that each of the three Indian studies displayed adequate statistical power through post-hoc power analysis, meta-analysis would not be apt in the present context.

The *IGF2BP2* gene, located on chromosome 3q27.2, spans about 181.3 kb with 16 exons. It belongs to a family of mRNA-binding proteins (IMP1, IMP2 and IMP3) which are highly expressed in the pancreatic islets and are essential for normal embryonic growth and development ([@bb0045]). It encodes a protein which binds to the 5′ UTR of the IGF2 (*Insulin growth factor 2*) m-RNA and thus regulates translation of the IGF2 gene. However, the precise role of intronic SNPs of this gene in the etiology of T2DM is still to be understood, notwithstanding their presumptive involvement in the alternative splicing and thereby in gene regulation. On the other hand, the *SLC30A8* gene, which is located on chromosome 8q24.11, spans about 226.44 kb with 11 exons and belongs to zinc transporter family, which is specific to pancreas and highly expressed in the insulin secreting beta cells. This gene encodes for a Zn transporter protein (ZnT8), which facilitates accumulation of zinc from the cytoplasm into intracellular vesicles, where the insulin is stored ([@bb0040]). The rs13266634 polymorphism is a non-synonymous mutation located in the last exon of *SLC30A8*, causing an amino acid change -- arginine (R) to tryptophan (W) -- at position 325 (R325W). It is assumed that the variants in this gene may influence the Zn transporter, affecting insulin stability and insulin secretion. Most of the functional studies hitherto were based on the expression levels of *IGF2BP2* and *SLC30A8* in the pancreatic beta cells to establish the role of these genes in the etiology of T2DM, but the precise role of variants of these genes is still unclear. Therefore, further studies need to be focussed on the exact mechanisms by which these variants of *IGF2BP2* and *SLC30A8* influence the expression in the pancreatic beta cells, which may provide new insights into the molecular mechanisms that may have possible role in the etiology of T2DM.

Despite biological significance of these genes in the pathophysiology of T2DM, it may be pertinent to note that the three SNPs considered for this study are only index variants, initially found to be associated in European populations. These are not causal variants, but mainly surrogates linked to the functional variants and given the difference in LD across populations these SNPs may not tag the same causal variants in different populations, even if they share same causal variants. This would partly explain why certain populations fail to replicate the association pattern observed earlier among the European populations. It is also possible that these loci are not implicated in T2DM or that different causal variants are prevalent at the two loci in different populations. The evidence for differential genetic predisposition of Indian populations (as compared to the Caucasians) is already available with reference to different complex disorders such as recurrent miscarriages, PCOS, cardiomyopathies etc. ([@bb0005; @bb0050; @bb0055]). Given the complexity of Indian population, the studies hitherto focussed on molecular genetic association with T2DM are too few to draw any representative picture for India. A number of populations from different regions and ethnicities need to be screened for different candidate genes, not only to validate already known variants but also to see if any new genetic variants that are unique to Indian populations can be found.
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###### 

Clinical profile of the T2DM cases and controls[b](#tf0005){ref-type="table-fn"}.

  Variables                       Mean[a](#tf0015){ref-type="table-fn"}   Median          Range                          
  ------------------------------- --------------------------------------- --------------- -------- -------- ------------ ------------
  Age                             52.5 (9.08)                             52.20(7.55)     52.00    50.00    31--80       40--85
  Age at onset (yrs) of T2DM      44.78 (8.65)                            --              45.00    --       25--71       --
  Duration of the disease (yrs)   9.18 (7.69)                             --              7.00     --       1--38        --
  BMI                             27.07 (4.63)                            24.72(4.62)     26.5     24.80    13.0--44.1   12.8--29.0
  WHR                             1.69 (0.43)                             0.94(0.03)      1.67     0.95     0.55--3.51   0.72--1.09
  FPG (mg/dl)                     115.50 (32.45)                          --              108.00   --       47--323      --
  PPG (mg/dl)                     195.71 (52.83)                          --              191.00   --       82--409      --
  RBG (mg/dl)                     199.27 (81.60)                          110.65(15.93)   185.50   108.00   73--520      70--139
  SBP (mm Hg)                     128.11 (10.73)                          --              130.00   --       94--180      --
  DBP (mm Hg)                     80.02 (8.57)                            --              80.00    --       20--215      --

Numbers in the parentheses are the SDs.

Control subjects were not measured for blood pressure and FPG and PPG.

###### 

Allele frequency distribution and odds ratios from logistic regression of T2DM on the IGF2BP2 (rs4402960, rs1470579) and SLC30A8 (rs13266634) SNPs in the population of Hyderabad.

  Gene        SNP          Major/minor allele   Cases (N = 758)   Controls (N = 621)   *χ*^2^   O.R.         (95% C.I.)   p value
  ----------- ------------ -------------------- ----------------- -------------------- -------- ------------ ------------ ---------
  IGF2BP2     rs4402960    G                    0.49              0.51                 1.52     1.10         0.95--1.28   0.22
  T           0.51         0.49                                                                                           
  rs1470579   A            0.49                 0.51              1.66                 1.11     0.95--1.29   0.20         
  C           0.51         0.49                                                                                           
  SLC30A8     rs13266634   C                    0.78              0.77                 0.31     *0.95*       0.79--1.14   0.58
  T           0.22         0.23                                                                                           

###### 

Frequency distribution of the genotypes of the three SNPs of IGF2BP2 and SLC30A8 genes in T2DM cases and controls and odds ratios from logistic regression of T2DM on genotype frequency using wild homozygote as reference and adjusted for co-variates.

  Gene        SNP          Genotype   Cases (N = 758)   Controls (N = 621)   *χ*^2^   p value      Genotypes   p value   O.R.         95% C.I.     Adjusted for BMI, WHR                
  ----------- ------------ ---------- ----------------- -------------------- -------- ------------ ----------- --------- ------------ ------------ ----------------------- ------------ ------------
  IGF2BP2     rs4402960    *GG*       0.23              0.27                 1.83     0.40         GT Vs GG    0.25      1.17         0.90--1.53   0.39                    1.13         0.86--1.49
  *GT*        0.51         0.49       TT Vs GG          0.22                 1.21     0.89--1.65   0.20        1.23      0.89--1.70                                                     
  **TT**      0.26         0.24                                                                                                                                                         
  rs1470579   *AA*         0.24       0.27              2.21                 0.33     AC Vs AA     0.18        1.20      0.92--1.56   0.30         1.16                    0.88--1.53   
  *AC*        0.50         0.48       CC Vs AA          0.20                 1.22     0.90--1.66   0.19        1.24      0.90--1.70                                                     
  ***CC***    0.26         0.24                                                                                                                                                         
  SLC30A8     rs13266634   *TT*       0.04              0.05                 2.63     0.27         TT Vs CT    0.22      1.39         0.82--2.34   0.29                    1.35         0.77--2.34
  *TC*        0.38         0.34       TT Vs CC          0.51                 1.19     0.71--1.97   0.55        1.18      0.67--2.03                                                     
  **CC**      0.58         0.61                                                                                                                                                         

###### 

Distribution of allele frequency for the two SNPs of IGF2BP2(rs4402960) and SLC30A8 (rs13266634)genes among the three Indian populations.

  Ref                                          Sample size   IGF2BP2 --- rs4402960   SLC30A8 --- rs13266634                                             
  -------------------------------------------- ------------- ----------------------- ------------------------ ------ ------ ------ ------ ------ ------ ------
  Current study                                758           621                     0.49                     0.51   0.51   0.49   0.78   0.22   0.77   0.23
  [@bb0165]                                    532           386                     0.57                     0.43   0.61   0.39   0.73   0.27   0.73   0.27
  [@bb0030]                                    2486          2678                    0.48                     0.42   0.44   0.56   0.80   0.20   0.77   0.23
  [@bb0035][a](#tf0010){ref-type="table-fn"}   926           812                     --                       --     --     --     --     --     --     --

Test for homogeneity *Χ*^2^ (df); p value (pooled cases - IGF2BP2) 14.2 (2); p \< 0.001 (pooled controls -IGF2BP2) 43.7 (2); p \< 0.0001 (pooled cases -SLC30A8) 13.3 (2); p \< 0.0014 (pooled controls -SLC30A8) 3.0 (2); p \> 0.223.

*Χ*^2^ (df); p (cases + controls) (IGF2BP2) 52.2 (2); p \< 0.0001 (SLC30A8) 13.4 (2); p \< 0.0013.

Allelic frequencies were not presented in the paper.
